Platelet Transfusion Refractoriness
7
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
Platelet Transfusion Refractoriness
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL